Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6PII3
UPID:
CC174_HUMAN
Alternative names:
-
Alternative UPACC:
Q6PII3; Q96CS5
Background:
Coiled-coil domain-containing protein 174 plays a crucial role in neuronal development, suggesting its pivotal involvement in the brain's structural and functional maturation. This protein's unique structure and function underscore its significance in neurobiological processes.
Therapeutic significance:
Linked to Hypotonia, infantile, with psychomotor retardation, a disorder characterized by congenital axial hypotonia, abducens nerve weakness, psychomotor developmental delay, brain ventriculomegaly, corpus callosum thinning, and cardiac septal defects, understanding the role of Coiled-coil domain-containing protein 174 could open doors to potential therapeutic strategies.